Teva, Celltrion launch their Rituxan biosimilar TruximaTeva and Celltrion's Truxima is the first biosimilar to Genentech’s Rituxan (rituximab). Sandoz gets FDA green light for Neulasta biosimilar ZiextenzoWith the FDA approval of Ziextenzo — a biosimilar of Neulasta — Sandoz is the first and only company to offer long- and short-acting filgrastim biosimilar treatment options. FDA approves third indication for Lupin’s generic Levoxyl Lupin's levothyroxine sodium tablets now is approved as a generic of Synthroid, Unithroid, and Levoxyl. Endo implements CEO succession plan Paul Campanelli has been named Endo chairman of the board, and will continue as president and CEO until a successor is appointed. Camber gets FDA nod for generic Bentyl Generic Bentyl is Camber's first injectable product to hit the market. SunGen gets FDA nod for lidocaine ointment Lidocaine has a market value of about $60 million. Alembic launches generic Tricor Alembic is launching generic Tricor tablets in two dosage strengths. Aurobindo’s generic Lodosyn gets FDA OK Carbidopa tablets had a market value of roughly $7.7 million for the 12 months ending August 2019, according to IQVIA. Lupin gets FDA nod for generic Depakote Divalproex sodium ER tablets, 250 mg and 500 mg had a market value of roughly $159 million, according to IQVIA June 2019 data. Alembic’s Aleor joint venture gets FDA green light for generic desonide Desonide ointment, 0.05%, had a market value of $13 million for the 12 months ended December 2018, according to IQVIA. First Previous 156 157 158 159 160 Next Last